If You Have Cancer in One Breast, Should You Get Both Removed?

For the vast majority of women diagnosed with cancer in one breast, removing the healthy opposite breast does not improve survival. A large study of over 100,000 women followed for up to 20 years found that the chance of dying from breast cancer was virtually the same whether women had lumpectomy, single mastectomy, or double mastectomy. The picture changes for women who carry certain inherited gene mutations, but even then the decision is more layered than it first appears. Understanding the actual numbers behind contralateral breast cancer risk, and how modern treatments have reshaped that risk, is the key to making a clear-headed choice.

What the Survival Data Shows

The strongest evidence against routine double mastectomy comes from studies tracking tens of thousands of women over many years. A 2024 study in JAMA Oncology found that 20-year breast cancer mortality was nearly identical across surgical approaches: about 16.3% for lumpectomy, 16.7% for single mastectomy, and 16.7% for bilateral mastectomy. The hazard ratio for dying of breast cancer after bilateral mastectomy compared with lumpectomy was 0.99, meaning essentially no difference at all.¹

An earlier California-based study of nearly 190,000 women found similar results at 10 years. Breast-conserving surgery with radiation had a 10-year mortality of roughly 17%, while bilateral mastectomy came in around 19%, with no statistically significant difference between them. Interestingly, single mastectomy was associated with somewhat higher mortality, possibly because women who chose it were less likely to receive radiation therapy.²

These findings build on decades of evidence. Randomized trials dating back to the 1980s showed that lumpectomy with radiation achieves the same overall survival as total mastectomy.³ The core reason is straightforward: for most breast cancers, the threat to life comes from cancer cells that have already spread beyond the breast at the time of diagnosis, not from new cancers growing in the other breast. Removing healthy tissue on the opposite side does nothing to address microscopic disease that may already be elsewhere in the body.

The Real Risk of Developing Cancer in the Other Breast

One of the biggest drivers of double mastectomy is fear of the cancer showing up on the other side. That fear is understandable, but the actual numbers tend to be far lower than patients believe. A study of breast cancer patients found that the average woman estimated her 10-year risk of contralateral breast cancer at about 31%.⁴ The reality for most women is a fraction of that.

Actual risk depends heavily on the biology of the first cancer. Women whose initial cancer is estrogen-receptor-negative (ER-negative) face higher contralateral risk: roughly 7% at five years and about 12% at ten years. Women with ER-positive cancers, who make up the majority of breast cancer patients, have lower rates, around 4% at five years and roughly 8% at ten years.⁵ Those ten-year figures are before factoring in the protective effect of hormonal therapies, which most ER-positive patients take.

So for the average woman without a high-risk genetic mutation, the yearly chance of developing cancer in the other breast is somewhere around half a percent to one percent per year. That is not negligible over a lifetime, but it is nowhere near the one-in-three odds many women imagine. Younger women diagnosed before age 40 do tend to perceive their risk as higher, and their risk genuinely is somewhat elevated compared with older patients, which partly explains the pull toward more aggressive surgery in that group.⁶

How Hormonal Therapy Lowers the Risk Further

For women with hormone-receptor-positive breast cancer, anti-estrogen medications like tamoxifen and aromatase inhibitors do more than fight the original cancer. They also substantially reduce the chance of cancer arising in the other breast. A large community-based study found that four years of tamoxifen use was associated with roughly a two-thirds reduction in contralateral breast cancer risk compared with non-use, and that benefit persisted for at least five years after stopping the drug.⁷

Aromatase inhibitors, used in postmenopausal women, offer similar protection. In a randomized trial of extended aromatase inhibitor therapy, the yearly rate of contralateral breast cancer was cut by more than half compared with placebo.⁸ In practical terms, for a woman already taking one of these drugs, the residual annual risk of cancer appearing in her other breast drops well below half a percent. At that level, the risk reduction from prophylactic removal of the healthy breast becomes extremely small in absolute terms, which is why the survival studies show no benefit.

When Genetics Change the Calculus

The one group for whom bilateral mastectomy genuinely shifts the odds is women carrying inherited mutations in high-penetrance breast cancer genes, particularly BRCA1 and BRCA2. These mutations substantially raise the lifetime risk of cancer in the opposite breast. A study of BRCA carriers estimated ten-year contralateral breast cancer risks of about 10% for both BRCA1 and BRCA2 carriers, roughly double to triple the rate seen in non-carriers.⁹

More importantly, unlike in non-carriers, there is evidence that contralateral mastectomy may actually improve survival in BRCA1/2 carriers. One retrospective study found a ten-year overall survival of 89% in BRCA carriers who chose contralateral mastectomy, compared with 71% in those who did not, and the benefit appeared to hold even after accounting for whether women also had their ovaries removed.¹⁰ A BMJ study using multivariable analysis reported a roughly 48% reduction in breast cancer death with contralateral mastectomy, though a more conservative matched analysis found the benefit was no longer statistically significant.¹¹ None of these are randomized trials, so the results need careful interpretation, but they are consistent enough that professional guidelines recommend discussing bilateral mastectomy with BRCA carriers.¹²

Beyond BRCA

Genetic testing now identifies mutations in several other genes associated with breast cancer, and the contralateral risk varies quite a bit among them. Carriers of CHEK2 mutations face a meaningfully elevated contralateral risk, with ten-year rates around 8%, and BRCA-level relative hazards in some analyses.¹³ PALB2 carriers fall into a gray zone: some studies find elevated contralateral risk, particularly for ER-negative disease, while others do not find a statistically significant increase overall. ATM carriers appear to have contralateral breast cancer rates that are not clearly higher than average.⁹

Who Clinical Guidelines Recommend It For

The Society of Surgical Oncology states that bilateral risk-reducing mastectomy should be discussed with individuals at high lifetime risk due to BRCA1/2 or other high-penetrance gene mutations, early chest radiation exposure, or a strongly suggestive family history. However, the same guidelines say it is not recommended for most patients with high-risk breast lesions and may actually be inadvisable for patients with other serious health conditions or high surgical-complication risk.¹⁴

What the Surgery Costs You Physically

Bilateral mastectomy is a bigger operation with more recovery time and a higher complication rate. A large national surgical quality database found that women who underwent bilateral mastectomy had about twice the odds of a longer hospital stay and roughly two to three times the odds of needing a blood transfusion compared with women who had a unilateral procedure. Those who chose implant-based reconstruction had a modestly higher reoperation rate, while those who had tissue-based (autologous) reconstruction had significantly more wound-healing problems.¹⁵ Rates of infection and medical complications were similar between the two, but the overall burden of a double surgery is measurably greater.

There is also a financial dimension. One study estimated that adding prophylactic removal of the healthy breast to a planned mastectomy with reconstruction cost an additional $12,000 on average, driven primarily by longer operating time and more follow-up procedures.¹⁶

Symmetry, Satisfaction, and Body Image

One area where bilateral mastectomy does appear to offer a tangible advantage is cosmetic symmetry after reconstruction. Multiple studies using validated patient-reported outcome tools have found that women who undergo bilateral mastectomy with reconstruction rate their breast satisfaction, symmetry, and aesthetics higher than women who have only one side reconstructed.¹⁷¹⁸ The difference makes intuitive sense: matching two reconstructed breasts is generally easier than matching a reconstructed breast with a natural one.

The picture is more nuanced for unilateral reconstruction, where satisfaction depends heavily on reconstruction type. Women who had tissue-based (autologous) unilateral reconstruction reported much higher general and aesthetic satisfaction than those who had implant-based unilateral reconstruction. In the bilateral group, satisfaction was more consistent regardless of reconstruction method.¹⁹ In other words, if you are concerned about cosmetic outcome with a single-breast reconstruction, the type of reconstruction may matter as much as whether you remove the other breast.

The symmetry benefit is real, but it sits alongside a finding that surprised researchers: breast satisfaction at 15 months after surgery was actually lower in women who had bilateral mastectomy than in women who had breast-conserving therapy, even though anxiety and fear-of-recurrence scores were similar across all groups.²⁰ Removing more tissue does not necessarily translate into feeling better about the result, or about the cancer.

Why Rates Climbed So Sharply

Despite the lack of a survival benefit, bilateral mastectomy for women with cancer in only one breast surged in popularity during the 2000s and 2010s. Among women who were candidates for breast-conserving surgery, the rate of bilateral mastectomy rose from under 2% in 1998 to over 11% in 2011.²¹ A more recent analysis of nearly a million patients showed the rate peaked around 2013 at about 16% before declining modestly to about 11% by 2020, likely reflecting growing awareness that double mastectomy does not improve outcomes for average-risk women.²²

Several forces drove the increase. The spread of genetic testing made more women aware of hereditary risk, and BRCA entered popular conversation. The availability of better reconstruction options, especially immediate implant reconstruction, made bilateral mastectomy feel less daunting. Among patients who received chemotherapy before surgery, bilateral mastectomy with immediate reconstruction specifically rose from about 8% to 13% over a study period.²³

But perhaps the most powerful driver was psychological. A review in JAMA Surgery noted that the anxiety created by a cancer diagnosis tends to focus on the contralateral breast, because it is the most concrete target a patient can act on. Fear of the cancer “coming back” often gets channeled into wanting the other breast removed, even though a new cancer in the opposite breast is a different disease from recurrence.²⁴ The deeply human desire to do “everything possible” is hard to argue with in the moment, even when the data suggests it will not change the outcome.

Racial and Socioeconomic Disparities

Who gets bilateral mastectomy tracks closely with demographics in ways that have little to do with medical indications. Analyses of national databases consistently find that younger women, white women, and women with private insurance are far more likely to choose contralateral prophylactic mastectomy. In a multivariable analysis, Black women had about 44% lower odds of undergoing the procedure compared with white women, and Hispanic women had about 39% lower odds, even after controlling for clinical stage and tumor biology.²⁵

A separate study of over 2,000 women in Pennsylvania and Florida found that 18% of white women chose contralateral prophylactic mastectomy compared with 10% of Black women, a gap that persisted after adjusting for clinical factors and family history.²⁶ This does not necessarily mean underuse by non-white women. Given that the surgery provides no survival benefit for most patients, the disparity may partly reflect differential access to reconstruction, differences in how risk is communicated, or different cultural attitudes toward removing healthy tissue. It does highlight that the decision is shaped by factors well beyond medical need.

What MRI Reveals Before Surgery

Breast MRI has become an increasingly common part of pre-surgical workup, and it sometimes detects abnormalities in the opposite breast that were invisible on mammography. One study found that MRI changed the surgical plan in about 38% of women, including switching roughly 7% to bilateral surgery based on findings in the contralateral breast.²⁷ An Ontario clinical practice guideline recommended that preoperative MRI be considered on a case-by-case basis, noting its ability to detect synchronous contralateral cancers and improve treatment planning.²⁸

For women planning bilateral prophylactic mastectomy, preoperative MRI can serve as a useful check. In one study of high-risk patients, MRI detected all occult cancers before surgery, which could affect the type of mastectomy and reconstruction chosen.²⁹ That said, MRI also generates false-positive findings that can lead to unnecessary biopsies and heightened anxiety. It is a powerful tool but needs to be used selectively rather than routinely for every patient.

How Decision Aids Help

Given the gap between perceived and actual risk, formal decision aids can make a real difference. A randomized trial found that women who used a structured decision aid before surgery experienced significantly less decisional conflict, meaning they felt clearer about their values and more confident in their choice, regardless of which surgery they ultimately picked.³⁰

A systematic review of shared decision-making tools in breast cancer surgery found that these interventions consistently improved patient knowledge and reduced the gap between what patients wanted and what they chose. Three-dimensional visual aids and conversational decision tools were particularly effective and also helped close knowledge gaps for patients with lower education or income levels.³¹ The goal is not to talk anyone out of bilateral mastectomy. It is to make sure that whatever a woman decides, she is working from accurate numbers rather than inflated fears. For the relatively small group of women with genuine high-risk genetics, those same tools can help clarify that bilateral mastectomy is a medically reasonable option worth serious consideration, not just an emotional reaction.